Search Results

You are looking at 31 - 40 of 347 items for :

  • "metabolic disease" x
  • Refine by Access: All content x
Clear All
Free access

Guohong Liu, Mirta Grifman, James Macdonald, Peter Moller, Flossie Wong-Staal, and Qi-Xiang Li

), increase adiponectin levels ( Combs et al. 2002 ). All these studies indicate that adiponectin might be an important therapeutic molecule for metabolic diseases. The site and mechanism of the putative anti-diabetic action of adiponectin are

Free access

Odelia Katz, Matthew Stuible, Nathalia Golishevski, Lilach Lifshitz, Michel L Tremblay, Max Gassmann, Moshe Mittelman, and Drorit Neumann

and attenuation of body weight gain, thus bearing significant clinical implications in the management of a wide range of metabolic diseases. Materials and Methods Mice Female mice of the inbred strains BALB/c and C57BL/6, aged 8 and 12 weeks

Free access

Mark A Exley, Laura Hand, Donal O'Shea, and Lydia Lynch

subjects after surgery-induced weight loss . Diabetes 54 2277 – 2286 . ( doi:10.2337/diabetes.54.8.2277 ) Chawla A Nguyen KD Goh YP 2011 Macrophage-mediated inflammation in metabolic disease . Nature Reviews. Immunology 11 738 – 749

Free access

Terese M Zidon, Jaume Padilla, Kevin L Fritsche, Rebecca J Welly, Leighton T McCabe, Olivia E Stricklin, Aaron Frank, Youngmin Park, Deborah J Clegg, Dennis B Lubahn, Jill A Kanaley, and Victoria J Vieira-Potter

adipose tissue (WAT) dysfunction ( Lovejoy et al. 2008 , Bluher 2009 , 2013 , Vieira-Potter et al. 2015 ). Thus, E 2 deficiency increases the risk for developing obesity-related cardiovascular and metabolic diseases, such as type 2 diabetes

Free access

Amy Warner and Jens Mittag

could be turned to burning fuel instead of storing. This review summarizes the current knowledge on thermogenic adipose tissue and discusses its possible use in elevating energy expenditure to counteract obesity and metabolic diseases such as type 2

Free access

Manuela Elsen, Silja Raschke, and Jürgen Eckel

that recombinant irisin and FNDC5 induce browning of WAT-derived murine preadipocytes in vitro . In the context of irisin as a therapeutic approach in the fight against obesity and its associated metabolic diseases, it is crucial to prove that irisin

Free access

Patricia Cristine Borck, Sarah Rickli, Jean Franciesco Vettorazzi, Thiago Martins Batista, Antonio Carlos Boschero, Elaine Vieira, and Everardo Magalhães Carneiro

rhythms induced by unbalanced consumption of nutrients on diet, which could enhance the pathophysiological features of metabolic diseases. Indeed, mice fed to high-fat diet (HFD) and exposed to ALAN exhibited higher body and fat pads weights, lower energy

Free access

Melanie Tran, Linda A Gallo, Andrew J Jefferies, Karen M Moritz, and Mary E Wlodek

uteroplacental insufficiency, growth-restricted female rats developed loss of glucose control on day 20 of pregnancy in the absence of obesity ( Gallo et al . 2012 b ). Therefore, in this study, we determined whether metabolic disease risk (impaired glucose

Open access

Vicki Chen, Gia V Shelp, Jacob L Schwartz, Niklas D J Aardema, Madison L Bunnell, and Clara E Cho

( Armitage et al. 2005 , Kind et al. 2006 ). However, limited attention has been on the role of micronutrient intakes during pregnancy in programming the long-term phenotypes of offspring. Concurrent with the increased prevalence of metabolic diseases

Free access

Sojin Lee and H Henry Dong

feature of FoxO6 protein ( Fig. 1 ). FoxO6 expression becomes deregulated in metabolic disease. Furthermore, altered FoxO6 expression in the brain is associated with impaired cognitive function in mice. In this article, we provide a comprehensive review on